Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Zina Goldvekht

Physician Assistant Forest Hills, NY Physician Assistant

NPI 1164480844 CMS profile 10546651

6405 Yellowstone Blvd, Cfu 101, Forest Hills, NY 11375

Open in the dashboard

General payments

$9,112

418 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zina Goldvekht of Forest Hills, NY is reported in the CMS Open Payments database as having received $9,112 across 418 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,054 92
2024 General $2,011 94
2023 General $2,008 87
2022 General $1,581 75
2021 General $1,458 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zina Goldvekht
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Zina Goldvekht were reported at $2,054. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Zina Goldvekht Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,458 $132 $37–$438 $132
2022 $1,581 $155 $48–$522 $149
2023 $2,008 $167 $52–$557 $160
2024 $2,011 $178 $55–$600 $164
2025 $2,054 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,426 68 payments
  2. Genzyme Corporation $1,080 40 payments
  3. Janssen Biotech, Inc. $1,053 45 payments
  4. Pfizer Inc. $722 33 payments
  5. Sun Pharmaceutical Industries Inc. $713 35 payments
  6. Lilly USA, LLC $613 26 payments
  7. Arcutis Biotherapeutics, Inc. $516 35 payments
  8. Regeneron Healthcare Solutions, Inc. $457 14 payments
  9. Dermavant Sciences, Inc. $416 17 payments
  10. Incyte Corporation $379 18 payments
  11. Other $1,735 87 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,655 412 payments
  2. Education $457 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $944 33 payments
  2. TREMFYA $938 40 payments
  3. SKYRIZI $829 42 payments
  4. CIBINQO $577 26 payments
  5. EUCRISA $522 25 payments
  6. Zoryve $497 34 payments
  7. ILUMYA $492 23 payments
  8. TALTZ $461 20 payments
  9. VTAMA $444 18 payments
  10. DUPIXENT Inflammation And Immunology $429 13 payments
  11. Other $3,820 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,910

Median for Physician Assistant: 241

Drug cost

$381,185

Median for Physician Assistant: $4,110

Branded share of claims

15.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 71 $134,955
Otezla Apremilast Brand 17 $75,948
Jublia Efinaconazole Brand 54 $55,086
Vtama Tapinarof Brand 26 $34,781
Zoryve Roflumilast Brand 22 $18,540
Ketoconazole Generic 348 $11,158
Metronidazole Generic 116 $8,165
Tacrolimus Generic 45 $7,708
Clobetasol Propionate Generic 175 $6,791
Calcipotriene Generic 35 $4,866

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$16,423

Medicare's payments for the services billed

Medicare patients

68

Average age 79

Services billed

226

45 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 62%
Ischemic heart disease 49%
Depression 41%
COPD 31%
Osteoporosis 31%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $275
  • Regeneron Healthcare Solutions, Inc. $91
$366 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $305
$305 22 —
TREMFYA
  • Janssen Biotech, Inc. $234
$234 — —
VTAMA
  • Dermavant Sciences, Inc. $224
$224 26 —
SKYRIZI
  • AbbVie, Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record